Volume 84, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



The therapeutic efficacies of 3-day regimens of artesunate-amodiaquine and artemether-lumefantrine during 5 years of adoption as first-line treatments were evaluated in 811 ≤ 12-year-old malarious children. Compared with artemether-lumefantrine, amodiaquine-artesunate significantly reduced the proportion of children with fever and parasitemia 1 day after treatment (day 1; < 0.008 for both). The proportion of parasitemic children on day 2 and gametocytemia on presentation and carriage reduced significantly over the years ( < 0.000001 and < 0.03, respectively; test for trend). Overall efficacy was 96.5% (95% confidence interval [CI] = 94.5–98.6) and remained unchanged over the years ( = 0.87; test for trend). Kinetics of parasitemias after treatments were estimated by a non-compartmental model. Declines of parasitemias were monoexponential, with a mean elimination half-life of 1.09 hours (95% CI = 1.0–1.16). Parasitemia half-lives and efficacy were similar for both regimens and in all ages. Artesunate-amodiaquine and artemether-lumefantrine remain efficacious treatments of uncomplicated falciparum malaria in Nigerian children 5 years after adoption.


Article metrics loading...

Loading full text...

Full text loading...



  1. World Health Organization, 2001. Antimalarial Drug Combination Therapy. Report of a WHO Technical Consultation. Geneva, Switzerland: World Health Organization.
  2. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N, , International Artemisinin Study Group, 2004. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363: 917.[Crossref]
  3. Bosman A, Mendis KN, , 2007. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg 77 (Suppl 6): 193197.
  4. World Health Organization, 2006. Facts on Artemisinin Based Combination Therapies. Geneva, Switzerland: World Health Organization. Available at: http://www.rollbackmalaria.org/cmc-upload/0/000/015/364/RBMInfosheet-9.htm. Accessed December 7, 2010.
  5. Dondorp AM, Nosten F, Poravuth Y, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh K, Socheat D, White NJ, , 2009. Artemisinin resistance in Plasmodium falciparum . N Engl J Med 361: 455467.[Crossref]
  6. World Health Organization, 1973. Chemotherapy of Malaria and Resistance to Antimalarials. Geneva, Switzerland: World Health Organization.
  7. World Health Organization, 2003. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. Geneva, Switzerland: World Health Organization.
  8. Oduola AMJ, Sowunmi A, Milhous WK, Martin RK, Walker O, Salako LA, , 1992. Innate resistance to new antimalarial drugs in Plasmodium falciparum from Nigeria. Trans R Soc Trop Med Hyg 86: 123126.[Crossref]
  9. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WRJ, , 2002. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomized, multicentre trial. Lancet 359: 13651372.[Crossref]
  10. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P, , 2009. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 3: CD007483.
  11. Salako LA, Ajayi FO, Sowunmi A, Walker O, , 1990. Malaria in Nigeria: a revisit. Ann Trop Med Parasitol 84: 435445.[Crossref]
  12. Sowunmi A, Gbotosho GO, Happi CT, Adedeji AA, Fehintola FA, Folarin OA, Tambo E, Fateye BA, , 2007. Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria. Am J Trop Med Hyg 77: 235241.
  13. Gbotosho GO, Sowunmi A, Okuboyejo TM, Happi CT, Folarin OO, Michael SO, Adewoye EO, , 2011. Therapeutic efficacy and effects of artemether-lumefantrine and artesunate-amodiaquine co-formulated or co-packaged, on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in southwest Nigeria. Am J Trop Med Hyg 84: 813819.[Crossref]
  14. Sowunmi A, Balogun T, Gbotosho GO, Happi CT, Adedeji AA, Fehintola FA, , 2007. Activities of amodiaquine, artesunate, and artesunate-amodiaquine against asexual- and sexual-stage parasites in falciparum malaria in children. Antimicrob Agents Chemother 51: 16941699.[Crossref]
  15. Sowunmi A, Gbotosho GO, Happi C, Okuboyejo T, Folarin O, Balogun S, Michael O, , 2009. Therapeutic efficacy and effects of artesunate-mefloquine and mefloquine alone on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in southwest Nigeria. Am J Trop Med Hyg 81: 979986.[Crossref]
  16. Michael OS, Gbotosho GO, Folatin OA, Okuboyejo T, Sowunmi A, Oduola AMJ, , 2010. Early variation in Plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance. Malar J 9: 335.[Crossref]
  17. World Health Organization, 2000. Severe falciparum malaria. Trans R Soc Trop Med Hyg 94 (Suppl 1): 190.
  18. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O'Neil M, Milhous W, Wirth DF, Oduola AMJ, , 2009. Selection of Plasmodium falciparum multi-drug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother 53: 888895.[Crossref]
  19. Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, Kyle DE, Milhous W, Wirth DF, Oduola AMJ, , 2006. Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. Am J Trop Med Hyg 75: 155161.
  20. Sowunmi A, Falade AG, Adedeji AA, Ayede AI, Fateye BA, Sowunmi CO, Oduola AMJ, , 2001. Comparative Plasmodium falciparum kinetics during treatment with amodiaquine and chloroquine in children. Clin Drug Investig 21: 371381.[Crossref]
  21. Anonymous, 1994. Epi Info Version 6. A Word Processing Data Base and Statistics Program for Public Health on IBM-Compatible Microcomputers. Atlanta, GA: Centers for Disease Control and Prevention.
  22. Anonymous, 1999. SPSS for Windows Release 10.01 (Standard Version). Chicago, IL: SPSS Inc.
  23. Happi CT, Gbotosho GO, Falade CO, Akinboye DO, Gerena L, Hudson T, Sowunmi A, Kyle DE, Milhous W, Wirth DF, Oduola AMJ, , 2003. Point mutation in the pfcrt and pfmdr-1 genes of Plasmodium falciparum and clinical response to chloroquine among malaria patients from Nigeria. Ann Trop Med Parasitol 97: 439451.[Crossref]
  24. Happi TC, Gbotosho GO, Folarin OA, Akinboye DO, Yusuf BO, Ebong OO, Sowunmi A, Kyle DE, Milhous W, Wirth DF, Oduola AMJ, , 2005. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop 95: 183193.[Crossref]
  25. Sowunmi A, Fateye BA, Adedeji AA, Fehintola FA, Gbotosho GO, Happi TC, Tambo E, Oduola AMJ, , 2005. Predictors of the failure of treatment with chloroquine in children with acute, uncomplicated, Plasmodium falciparum malaria, in an area with high and increasing incidences of chloroquine resistance. Ann Trop Med Parasitol 99: 535544.[Crossref]
  26. Sowunmi A, Fateye BA, Adedeji AA, Gbotosho GO, Happi TC, Bamgboye AE, Bolaji OM, Oduola AMJ, , 2006. Predictors of the failure of treatment with pyrimethamine-sulfadoxine in children with uncomplicated falciparum malaria. Acta Trop 98: 614.[Crossref]
  27. Federal Ministry of Health, 2004. National Malaria Treatment Policy. Abuja, Nigeria: Federal Ministry of Health.
  28. Federal Ministry of Health, 2005. National Antimalarial Treatment Guidelines. Abuja, Nigeria: Federal Ministry of Health.
  29. Meremikwu A, Alaribe A, Ejemot R, Oyo-Ita A, Ekenjoku J, Nwachukwu C, Ordu D, Ezedinachi E, , 2006. Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial. Malar J 5: 43.[Crossref]
  30. Falade CO, Ogundele AO, Yusuf BO, Ademowo OG, Ladipo SM, , 2008. High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. Trop Med Int Health 13: 635643.[Crossref]
  31. Olliaro P, Mussano P, , 2003. Amodiaquine for treating malaria. Cochrane Database Syst Rev 2: CD000016.
  32. Gbotosho GO, Sowunmi A, Okuboyejo TM, Happi CT, Folarin OO, Adewoye EO, , 2011. A simple dose regimen of artesunate-amodiaquine based on age or body weight range for uncomplicated falciparum malaria in children: comparison of therapeutic efficacy with standard dose regimen of artesunate-amodiaquine and artemether-lumefantrine. Am J Ther. doi:10.1097/MJT.0b013e318209e031.
  33. White NJ, , 1994. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans R Soc Trop Med Hyg 88 (Suppl 1): S41S43.[Crossref]
  34. Carrara VI, Zwang J, Ashley AA, Price RN, Stepniewska K, Brends M, Brockman A, Anderson T, McGready R, Phaiphun L, Proux S, van Vugt M, Hutagalung R, Lwin KM, Phyo AP, Preechapornkul P, Imwong M, Pukrittayakamee S, Singhasivanon P, White NJ, Nosten F, , 2009. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS ONE 4: e4551.[Crossref]
  35. Sowunmi A, Adewoye EO, Gbotosho GO, Happi CT, Sijuade A, Folarion OA, Okuboyejo TM, Michael OS, , 2010. Factors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children. Malar J 9: 53.[Crossref]
  36. Stepniewska A, Ashley A, Lee SJ, Anstey N, Barnes KI, Binh TQ, D'Alessandro U, day NPJ, de Vries PJ, Dorsey G, Guthmann J-P, Mayxay M, Newton PN, Olliaro P, Osorio L, Price RN, Rowland M, Smithuis F, Taylor WRJ, Nosten F, White NJ, , 2010. In vivo parasitological measures of artemisinin susceptibility. J Inf Dis 201: 570579.[Crossref]
  37. Mokuolu OA, Okoro EO, Ayetoro SO, Adewara AA, , 2007. Effect of artemisinin-based treatment policy on consumption pattern of antimalarials. Am J Trop Med Hyg 76: 711.
  38. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo AP, Naing AL, Nyo MY, Myint NZ, Imwong M, Ashley E, Lee SJ, White NJ, , 2010. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomized trial. Lancet Infect Dis 10: 673683.[Crossref]
  39. de Vries JP, Bich NN, Thien HV, Hung LN, Anh TK, Kager PA, Hiesterkamp SH, , 2000. Combinations of artemisinin and quinine for uncomplicated falciaprum malaria: efficacy and pharmacodynamics. Antimicrob Agents Chemother 44: 13021308.[Crossref]
  40. Wongsrichanalai C, Meshnick SR, , 2008. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis 14: 716719.[Crossref]
  41. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, , 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359: 26192620.[Crossref]
  42. Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, Yi P, Bouth DM, Bouchier C, Puijalon OM, Meshnick SR, Wongrichanalai C, Fandeur T, Le Bras J, Ringwald P, Ariey F, , 2009. Pfmdr 1 copy number and artemisinin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J 8: 11.[Crossref]
  43. Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, Rutvisuttinunt W, Bethell D, Surasri S, Fukuda MM, Socheat D, Chan Thap L, , 2010. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis 51: e82e89.[Crossref]

Data & Media loading...

  • Received : 23 Dec 2010
  • Accepted : 21 Feb 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error